Stonebridge Capital Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-314
| Closed | -$2.55K | – | 1034 |
|
|
2023
Q1 | $2.55K | Hold |
314
| – | – | ﹤0.01% | 786 |
|
|
2022
Q4 | $3.73K | Hold |
314
| – | – | ﹤0.01% | 734 |
|
|
2022
Q3 | $4K | Hold |
314
| – | – | ﹤0.01% | 723 |
|
|
2022
Q2 | $11K | Hold |
314
| – | – | ﹤0.01% | 584 |
|
|
2022
Q1 | $13K | Hold |
314
| – | – | ﹤0.01% | 633 |
|
|
2021
Q4 | $13K | Hold |
314
| – | – | ﹤0.01% | 602 |
|
|
2021
Q3 | $21K | Sell |
314
-315
| -50% | -$21.1K | ﹤0.01% | 488 |
|
|
2021
Q2 | $45K | Buy |
629
+315
| +100% | +$22.5K | ﹤0.01% | 490 |
|
|
2021
Q1 | $21K | Hold |
314
| – | – | ﹤0.01% | 498 |
|
|
2020
Q4 | $11K | Hold |
314
| – | – | ﹤0.01% | 189 |
|
|
2020
Q3 | $17K | Hold |
314
| – | – | ﹤0.01% | 181 |
|
|
2020
Q2 | $12K | Hold |
314
| – | – | ﹤0.01% | 476 |
|
|
2020
Q1 | $8K | Hold |
314
| – | – | ﹤0.01% | 513 |
|
|
2019
Q4 | $15K | Sell |
314
-357
| -53% | -$17.1K | ﹤0.01% | 498 |
|
|
2019
Q3 | $33K | Hold |
671
| – | – | 0.01% | 381 |
|
|
2019
Q2 | $61K | Hold |
671
| – | – | 0.01% | 292 |
|
|
2019
Q1 | $99K | Hold |
671
| – | – | 0.02% | 179 |
|
|
2018
Q4 | $106K | Buy |
671
+207
| +45% | +$32.7K | 0.02% | 155 |
|
|
2018
Q3 | $114K | Hold |
464
| – | – | 0.02% | 163 |
|
|
2018
Q2 | $104K | Hold |
464
| – | – | 0.02% | 163 |
|
|
2018
Q1 | $114K | Hold |
464
| – | – | 0.03% | 165 |
|
|
2017
Q4 | $143K | Hold |
464
| – | – | 0.03% | 164 |
|
|
2017
Q3 | $170K | Buy |
464
+71
| +18% | +$26K | 0.04% | 163 |
|
|
2017
Q2 | $143K | Buy |
393
+72
| +22% | +$26.2K | 0.04% | 150 |
|
|
2017
Q1 | $96K | Buy |
321
+100
| +45% | +$29.9K | 0.03% | 149 |
|
|
2016
Q4 | $49K | Buy |
+221
| New | +$49K | 0.01% | 147 |
|